This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VLON vs. ELYM, OSTX, ATNM, NBRV, AADI, EGRX, PYRGF, NNVC, TAOX, and IBIOShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Eliem Therapeutics (ELYM), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), NanoViricides (NNVC), Synaptogenix (TAOX), and iBio (IBIO). Vallon Pharmaceuticals vs. Its Competitors Eliem Therapeutics OS Therapies Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals PyroGenesis Canada NanoViricides Synaptogenix iBio Eliem Therapeutics (NASDAQ:ELYM) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment. Which has more risk & volatility, ELYM or VLON? Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Comparatively, Vallon Pharmaceuticals has a beta of -1.14, meaning that its stock price is 214% less volatile than the S&P 500. Which has better valuation and earnings, ELYM or VLON? Vallon Pharmaceuticals has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Vallon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-4.25Vallon Pharmaceuticals$100K244.02-$7.02M-$0.78-2.32 Does the media favor ELYM or VLON? In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Vallon Pharmaceuticals'average media sentiment score. Company Overall Sentiment Eliem Therapeutics Neutral Vallon Pharmaceuticals Neutral Is ELYM or VLON more profitable? Eliem Therapeutics' return on equity of -47.03% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Vallon Pharmaceuticals N/A -230.48%-124.89% Do insiders & institutionals have more ownership in ELYM or VLON? 69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Vallon Pharmaceuticals shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 37.3% of Vallon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryEliem Therapeutics beats Vallon Pharmaceuticals on 5 of the 9 factors compared between the two stocks. Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VLON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.40M$736.37M$5.85B$10.14BDividend YieldN/A4.84%5.68%4.60%P/E Ratio-2.321.1775.4125.98Price / Sales244.0226.64514.54181.13Price / CashN/A19.5637.5660.44Price / Book10.066.6812.156.29Net Income-$7.02M-$4.13M$3.29B$271.07M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$1.81-11.7%N/A+289.0%$24.40M$100K-2.323ELYMEliem TherapeuticsN/A$2.38-3.6%N/A-70.0%$70.81MN/A-4.499News CoverageOSTXOS Therapies2.0702 of 5 stars$2.20+0.5%$18.00+718.2%-35.7%$69.62MN/A-2.78N/AAnalyst ForecastATNMActinium Pharmaceuticals3.0649 of 5 stars$1.61+0.6%$4.50+179.5%-16.2%$50.23MN/A-1.1630Positive NewsShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.80+0.6%N/A+13.6%$44.46M$25.07M-0.7940EGRXEagle PharmaceuticalsN/A$3.21flatN/A-16.2%$41.69M$257.55M0.00100Gap DownPYRGFPyroGenesis CanadaN/A$0.17-0.6%N/A-66.8%$32.80M$9.14M-2.9290NNVCNanoViricides0.1518 of 5 stars$1.43-2.1%N/A-13.7%$22.98MN/A-1.9920Short Interest ↑TAOXSynaptogenix0.1128 of 5 stars$6.59+5.6%N/AN/A$21.76MN/A-0.334IBIOiBio1.6739 of 5 stars$0.88+6.0%$5.00+466.4%-50.9%$17.35M$375K-0.51100Short Interest ↑Gap Down Related Companies and Tools Related Companies ELYM Alternatives OSTX Alternatives ATNM Alternatives NBRV Alternatives AADI Alternatives EGRX Alternatives PYRGF Alternatives NNVC Alternatives TAOX Alternatives IBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VLON) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VLON Stock Alerts